125962-37-0

Basic information

• Product Name: 2-amino-9-[3-(hydroxymethyl)cyclobutyl]-3,9-dihydro-6H-purin-6-one
• Synonyms: 6H-Purin-6-one, 2-amino-1,9-dihydro-9-(3-(hydroxymethyl)cyclobutyl)-, cis-; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[3-(hydroxymethyl)cyclobutyl]-, cis-; cis-9-(3-(Hydroxymethyl)cyclobutyl)guanine; cis-9-[3-(Hydroxymethyl)cyclobutyl]guanine
• CAS NO: 125962-37-0
• Molecular Formula: C₁₀H₁₃N₅O₂
• Molecular Weight: 235.2425
• Mol File: 125962-37-0.mol

Chemical Properties

• Boiling Point: 594.4°C at 760 mmHg
• Flash Point: 313.3°C
• Density: 1.89g/cm³
• Vapor Pressure: 5.61E-15mmHg at 25°C
• Refractive Index: 1.896
• CAS DataBase Reference: 2-amino-9-[3-(hydroxymethyl)cyclobutyl]-3,9-dihydro-6H-purin-6-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-amino-9-[3-(hydroxymethyl)cyclobutyl]-3,9-dihydro-6H-purin-6-one(125962-37-0)
• EPA Substance Registry System: 2-amino-9-[3-(hydroxymethyl)cyclobutyl]-3,9-dihydro-6H-purin-6-one(125962-37-0)

Safety Data

• Hazardous Substances Data: 125962-37-0(Hazardous Substances Data)

Usage

General Description

2-Amino-9-[3-(hydroxymethyl)cyclobutyl]-3,9-dihydro-6H-purin-6-one is a chemical compound with a purine base structure. It contains an amino group and a cyclic hydroxymethyl group, making it a nucleoside analog. Nucleoside analogs are commonly used as antiviral or antineoplastic agents due to their ability to disrupt the replication of viral or cancerous DNA. The specific structure of 2-amino-9-[3-(hydroxymethyl)cyclobutyl]-3,9-dihydro-6H-purin-6-one suggests that it may have potential medical applications, particularly in the field of antiviral or anticancer therapy, although further research may be needed to fully understand its pharmacological properties and potential uses.

Upstream product

• 130368-76-2 (cis)-2-Amino-1,9-dihydro-9 [3-(hydroxymethyl)cyclobutyl]-6H-purine-6-one 
• 130369-03-8 [3-(2-Amino-6-chloro-purin-9-yl)-cyclobutyl]-methanol 
• 172324-70-8 (1r,3r)-3-((benzyloxy)methyl)cyclobutyl 4-nitrobenzoate 
• 172324-67-3 3-benzyloxymethyl-cyclobutanone 
• 172324-68-4 (1s,3s)-3-((benzyloxy)methyl)cyclobutanol 
• 172324-65-1 (1r,3r)-3-((benzyloxy)methyl)cyclobutanol 
• 172324-62-8 9--6-(4-chlorophenylsulfanyl)-2-(phenylacetamido)-9H-purine 
• 172324-61-7 9--2-N-(phenylacetyl)guanine 
• 1026560-19-9 6-(4-chlorophenylsulfanyl)-2-(phenylacetamido)-9H-purine 
• 172324-66-2 3-(benzyloxymethyl)-2,2-dichlorocyclobutanone 
• 158665-14-6 2-amino-6-(4-chlorophenylsulfanyl)-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine 
• 172324-60-6 9--2-N-(phenylacetyl)guanine 
• 132332-82-2 cis-6-chloro-9-(3-trityloxymethylcyclobutyl)purine 

Relevant articles and documents

CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF

An object of the present invention is to provide a compound exhibiting an excellent drug efficacy as an anti-adenoviral agent, and an anti-adenoviral agent. The present invention provides a compound represented by General Formula [1] (in the formula, R1 represents a halogen atom, an amino group which may be substituted, a C1-6 alkoxy group which may be substituted, a hydroxyl group which may be protected, or the like; R2 represents a hydrogen atom or an amino protecting group; R3 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like; R4 represents a C1-20 alkoxy group which may be substituted, an aryloxy group which may be substituted, an amino group which may be substituted, or the like); or a salt thereof.

Synthesis of 9--adenine and -guanine

2,2-Dichloro-3-(benzyloxymethyl)cyclobutanone 15, which was prepared in 50percent yield by the cycloaddition of dichloroketene to allyl benzyl ether 14, was converted in four steps and in ca. 40percent overall yield into trans-3-(benzyloxymethyl)cyclobutanol 11b.The latter alcohol 11b was coupled under Mitsunobu conditions with 6-(4-chlorophenylsulfanyl)-9H-purine 21b and 6-(4-chlorophenylsulfanyl)-2-(phenylacetamido)-9H-purine 21c to give the 9-cyclobutylpurine derivatives 22 and 24, respectively, in 88 and 60percent yield.The former product 22 was converted in three steps and in 39percent overall yield into 9-adenine 6, and the latter product was converted in four steps and in 42percent overall yield into 9-guanine 7.X-Ray crystallographic data relating to compounds 22 and 24 are also reported.

Novel cyclobutane Derivatives, processes for their preparation and pharmaceutical compositions comprising them

The invention is directed to cyclobutane derivatives represented by general formula (I): wherein A represents a hydrogen atom, a hydroxy group, an azido group or an amino group; and B represents a purine residue or a pyrimidine residue. The cyclobutane de